Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: A comparative study of managed entry agreements across seven European countries

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Morel, Thomas ^a   Arickx, Francis ^b   Befrits, Gustaf ^c   Siviero, Paolo ^d   Van Der Meijden, Caroline ^e   Xoxi, Entela ^d   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b National Institute for Health and Disability Insurance   (Belgium)

^c Dental and Pharmaceutical Benefits Agency   (Sweden)

^d ITALIAN MEDICINES AGENCY   (Italy)

^e Health Care Insurance Board ^*  (Netherlands)

Author keywords

Access; Health technology assessment; Managed entry agreements; Orphan drugs; Orphan medicinal products; Payers; Performance; Pricing; Reimbursement; Risk sharing; Uncertainty

Indexed keywords

ANTINEOPLASTIC AGENT; ORPHAN DRUG;

ACCURACY; ARTICLE; BELGIUM; CLINICAL PRACTICE; COMPARATIVE STUDY; CONFIDENTIALITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EUROPE; FRANCE; GEOGRAPHIC DISTRIBUTION; GERMANY; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; ITALY; MANAGED ENTRY AGREEMENT; NATIONAL HEALTH INSURANCE; NATIONAL HEALTH SERVICE; NETHERLANDS; OUTCOME ASSESSMENT; PREVALENCE; PUBLIC HEALTH; REIMBURSEMENT; SWEDEN; TAXONOMY; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; EUROPE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; ORPHAN DRUG PRODUCTION;

EID: 84890841035     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-198     Document Type: Article

References (66)

1. Regulation (EC) No 141/2000 of the European parliament and of the council of 16 december 1999 on orphan medicinal products. European Union, Official Journal of the European Communities, L18/1, 22/01/2000 2000 Ref Type: Bill/Resolution
2. Access to orphan drugs despite poor quality of clinical evidence. Dupont AG, Van Wilder PB, Br J Clin Pharmacol 2011 71 488 496 10.1111/j.1365-2125.2010. 03877.x 21395641
3. Orphan drug development is not taking off. Joppi R, Bertele V, Garattini S, Br J Clin Pharmacol 2009 67 5 494 502 10.1111/j.1365-2125.2009.03369.x 19552743
4. Orphan drugs, orphan diseases: the first decade of orphan drug legislation in the EU. Joppi R, Bertele' V, Garattini S, Eur J Clin Pharmacol 2013 69 1009 1024 10.1007/s00228-012-1423-2 23090701
5. Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Kanters TA, de Sonneville-Koedoot C, Redekop WK, Hakkaart L, Orphanet J Rare Dis 2013 8 124 10.1186/1750-1172-8-124 23947946
6. Characteristics of clinical trials to support approval of orphan vs non-orphan drugs for cancer. Kesselheim AS, Myers JA, Avorn J, JAMA 2011 305 2320 2326 10.1001/jama.2011.769 21642684
7. EU marketing authorization review of orphan and non-orphan drugs does not differ. Putzeist M, Mantel-Teeuwisse AK, Llinares J, Gispen-De Wied CC, Hoes AW, Leufkens HG, Drug Discov Today 2013 18 1001 1006 10.1016/j.drudis.2013.06. 012 23835230
8. Extraordinary pricing of orphan drugs: is it a socially responsible strategy for the U.S. pharmaceutical industry? Hemphill TA, J Bus Ethics 2010 94 225 242 10.1007/s10551-009-0259-x
9. The prevalence and cost of unapproved uses of top-selling orphan drugs. Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J, PLoS One 2012 7 31894 10.1371/journal.pone.0031894 22363762
10. Pricing for orphan drugs: will the market bear what society cannot? O'Sullivan BP, Orenstein DM, Milla CE, JAMA 2013 310 1343 1344 10.1001/jama.2013.278129 24084916
11. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Orofino J, Soto J, Casado MA, Oyaguez I, Appl Health Econ Health Policy 2010 8 301 315 10.2165/11531880-000000000-00000 20804223
12. Drugs for rare diseases: influence of orphan designation status on price. Picavet E, Dooms M, Cassiman D, Simoens S, Appl Health Econ Health Policy 2011 9 275 279 10.2165/11590170-000000000-00000 21682354
13. Orphan drug pricing may warrant a competition law investigation. Roos JC, Hyry HI, Cox TM, BMJ 2010 341 6471 10.1136/bmj.c6471 21081598
14. Pricing and reimbursement of orphan drugs: the need for more transparency. Simoens S, Orphanet J Rare Dis 2011 6 42 10.1186/1750-1172-6-42 21682893
15. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Schey C, Milanova T, Hutchings A, Orphanet J Rare Dis 2011 6 62 10.1186/1750-1172-6-62 21951518
16. The "weight" of orphan drugs in the European pharmaceutical policy: a focus on the expenditure and the utilization of orphan drugs in five European Union countries. Muscolo LAA, Deriu D, Sammarco A, Siviero PD, Pani L, Value Health 2012 15 20 Ref Type: Abstract
17. Coverage of orphan drugs: working with uncertainty? Morel T, Simoens S, The future of health economics Gower Publishing Ltd, Ethgen O, Staginnus U, in press
18. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. BMC Health Serv Res 2010 10 153 10.1186/1472-6963-10-153 20529296
19. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL, Health Policy 2010 96 179 190 10.1016/j.healthpol.2010.02.005 20226559
20. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Garrison LP Jr, Towse A, Briggs A, De PG, Grueger J, Mohr PE, et al. Value Health 2013 16 703 719 10.1016/j.jval.2013.04.011 23947963
21. What principles should govern the use of managed entry agreements? Klemp M, Fronsdal KB, Facey K, Int J Technol Assess Health Care 2011 27 77 83 10.1017/S0266462310001297 21262072
22. Access with evidence development schemes: a framework for description and evaluation. McCabe CJ, Stafinski T, Edlin R, Menon D, Pharmacoeconomics 2010 28 143 152 10.2165/11530850-000000000-00000 20085390
23. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Stafinski T, McCabe CJ, Menon D, Pharmacoeconomics 2010 28 113 142 10.2165/11530820-000000000-00000 20085389
24. Coverage with evidence development, only in research, risk sharing, or patient access scheme? a framework for coverage decisions. Walker S, Sculpher M, Claxton K, Palmer S, Value Health 2012 15 570 579 10.1016/j.jval.2011.12.013 22583469
25. Ministère des affaires sociales et de la sante publique et de l'environnement, Loi du 10 aout 2001 portant des mesures en matière de soins de sante (Article 35bis§7). Brussels, Belgium: Moniteur belge (NUMAC: 2001022579) 2001
26. Service public federal Securite sociale, Arrête royal du 11 fevrier 2010 modifiant l'arrête royal du 21 decembre fixant les procedures, delais et conditions en matière d'intervention de l'assurance obligatoire soins de sante et indemnites dans le cout de specialites pharmaceutiques (Articles 81-85) Brussels, Belgium: Moniteur belge (NUMAC: 2010022119) 2010
27. Department of Health, Cost effective provision of disease modifying therapies for people with multiple sclerosis: health service circular 2002/004 London: Department of Health 2002 Ref Type: Report
28. National Institute for Health and Clinical Excellence (NICE), Multiple sclerosis-beta interferon and glatiramer acetate: TA32 London: National Institute for Health and Clinical Excellence (NICE) 2002 Ref Type: Report
29. National Institute for Health and Clinical Excellence (NICE, Bortezomib for relapsed multiple myeloma: TA129 London: National Institute for Health and Clinical Excellence (NICE) 2007 Ref Type: Report
30. Department of Health, The pharmaceutical price regulation scheme (PPRS) 2009 London: Department of Health 2008 Ref Type: Report
31. National Health Service (NHS), Drugs attached to a risk sharing scheme (RSS) or patient access scheme (PAS): PAS04 London: National Health Service (NHS) 2013 Ref Type: Report
32. Department of Health, Patient access schemes and flexible pricing: statement of outcomes from the review of the pricing flexibility measures under chapter 6 of the 2009 PPRS London: Department of Health 2011 Ref Type: Report
33. National Institute for Health and Clinical Excellence (NICE), Sorafenib for the treatment of advanced hepatocellular carcinoma: TA189 London: National Institute for Health and Clinical Excellence (NICE) 2010 Ref Type: Report
34. Agenzia italiana del farmaco (AIFA), Determinazione 24 luglio 2006. Regime di rimborsabilita e prezzo di vendita della specialita medicinale Tarceva (erlotinib) 2006 Ref Type: Bill/Resolution
35. The Italian post-marketing registries. Xoxi E, Tomino T, de Nigro L, Pani L, Pharm Program 2012 5 57 60 10.1179/1757092112Z.0000000009
36. College voor zorgverzekeringen (CVZ), Guidance for outcomes research 'for the assessment of the cost-effectiveness of in-patient medicines': publicatienummer 270 Diemen: College voor zorgverzekeringen (CVZ) 2008 Ref Type: Report
37. College voor zorgverzekeringen (CVZ), Assessment cost-effectiveness and appropriate use-format results outcomes research for the re-assessment of an intramural drug within the framework of the NZa policy guidelines 'Expensive drugs' and 'Orphan drugs', four years after preliminary uptake Diemen: College voor zorgverzekeringen (CVZ) 2008 Ref Type: Report
38. Staatsblad van het Koninkrijk der Nederlanden, Besluit van 30 september 2011, houdende wijziging van het Besluit zorgverzekering in verband met wijziging van de te verzekeren prestaties Zorgverzekeringswet per 2012 en de eigen bijdragen daarvoor en wijziging van dat besluit en het Besluit zorgaanspraken AWBZ in verband met stringent pakketbeheer en wijziging van het Besluit tegemoetkoming chronisch zieken en gehandicapten: 2011/467 Rome: Agenzia italiana del farmaco (AIFA) 2011
39. College voor zorgverzekeringen (CVZ), Voorwaardelijk toegelaten specialistische geneesmiddelen (updated on October 1st 2012) Diemen: College voor zorgverzekeringen (CVZ) 2012 Ref Type: Online Source
40. European Medicines Agency (EMA), Assessment report for Myozyme: EMEA/CHMP/631070/2009 London: European Medicines Agency (EMA) 2009 Ref Type: Report
41. A randomized study of alglucosidase alfa in late-onset Pompe's disease. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. N Engl J Med 2010 362 1396 1406 10.1056/NEJMoa0909859 20393176
42. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG, Orphanet J Rare Dis 2013 8 29 10.1186/1750-1172-8-29 23421808
43. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs. Sheldon T, BMJ 2012 345 5461 10.1136/bmj.e5461 22890124
44. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Simoens S, Picavet E, Dooms M, Cassiman D, Morel T, Appl Health Econ Health Policy 2013 11 1 3 10.1007/s40258-012-0004-y 23329382
45. Le Cam Y, Viewpoint on behalf of EURORDIS at the public hearing by the package expert committee of the Dutch healthcare insurance board (CVZ) 2012 http://www.rarediseaseblogs.net/sept-21-2012-eurordis-intervention-at-dutch- healthcare-insurance-board-public-hearing/
46. Dutch Ministry for Health, Welfare and Sport, Vergoeding weesgeneesmiddelen voor de ziekte van Pompe en de ziekte van Fabry (Ministerial letter) 2013 URL: http://www.rijksoverheid.nl/regering/documenten-en- publicaties/kamerstukken/2013/01/30/kamerbrief-over-vergoeding- weesgeneesmiddelen-voor-ziekte-van-pompe-en-ziekte-van-fabry.html. Ref Type: Bill/Resolution
47. Tandvårds- och läkemedelsförmånsverket (TLV), Act on pharmaceutical benefits: (2002:160) Stockholm: Tandvårds- och läkemedelsförmånsverket (TLV) 2002
48. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Godman B, Gustafsson LL, Appl Health Econ Health Policy 2013 11 79 82 10.1007/s40258-012-0008-7 23322546
49. Threshold value for a QALY: correlation with disease severity and decision uncertainty. Hugosson K, Engstrom A, Value Health 2008 11 3 49 Ref Type: Abstract
50. Persson U, Value based pricing in Sweden: lessons for design? Seminar briefing no 12 Stockholm: Office of Health Economics 2012 Ref Type: Report
51. Ministère des affaires sociales et de la sante Accord cadre du 5 decembre 2012 entre le comite economique des produits de sante et le entreprises du medicament Paris: Ministère des affaires sociales et de la sante 2012
52. Comite economique des produits de sante (CEPS), Rapport d'activite 2009 Paris: Comite economique des produits de sante (CEPS) 2010
53. Comite economique des produits de sante (CEPS), Rapport d'activite 2008 Paris: Comite economique des produits de sante (CEPS) 2009 Ref Type: Report
54. Ministère des affaires sociales et de la sante Accord cadre entre le comite economique des produits de sante et le entreprises du medicament-modifie par l'avenant du 7 octobre 2010 Paris: Ministère des affaires sociales et de la sante 2010
55. GKV-Spitzenverband, AMNOG-Verhandlungen zum ersten Wirkstoff gegen seltene Krankheiten erfolgreich beendet 2012 URL: http://www.gkv-spitzenverband. de/presse/pressemitteilungen-und-statements/pressemitteilung-6529.jsp. Ref Type: Internet Communication
56. Bouvy J, Vogler S, Update on 2004 background paper, pricing and reimbursement policies: impacts on innovation: BP 8.3 Geneva: World Health Organisation (WHO) 2013 Ref Type: Report
57. European Commission (EC), Final report-working group on mechanism of coordinated access to Orphan medicinal products (MoCA-OMP) Brussels: Directorate-General for Enterprise and Industry 2013 Ref Type: Report
58. European Commission (EC), Key conclusions and recommendations-working group on mechanism of coordinated access to Orphan medicinal products (MoCA-OMP) Brussels: Directorate-General for Enterprise and Industry 2013 Ref Type: Report
59. European Commission (EC), Transparent value framework-working group on mechanism of coordinated access to Orphan medicinal products (MoCA-OMP) Brussels: Directorate-General for Enterprise and Industry 2013 Ref Type: Report
60. European Union Committee of Experts on Rare Diseases (EUCERD), Recommendation for a CAVOMP information flow Recommendation of the EU Committee of Experts on Rare Diseases to the European Commission and the Member States 2012 Ref Type: Report
61. New drugs and indications in 2012: sluggish progress, timid measures to protect patients. Prescrire 2013 33 352 134 137
62. Polish Parliament, Act on reimbursement of medicines, foodstuffs for special nutritional purposes and medical devices 2011 Ref Type: Bill/Resolution
63. Price agreement expected on cystic fibrosis drug Irish Times 2013 Ref Type: Newspaper
64. Dutch Ministry for Health, Welfare and Sport, Voorwaardelijke pakkettoelating specialistische geneesmiddelen (Ministerial letter) 2011 URL: http://www.rijksoverheid.nl/documenten-en-publicaties/brieven/2011/12/08/ brief-over-voorwaardelijke-pakkettoelating-specialistische-geneesmiddelen.html. Ref Type: Bill/Resolution
65. Dutch Ministry for Health, Welfare and Sport, Voorwaardelijke pakkettoelating farmacie (Ministerial letter) 2012 URL: http://www. rijksoverheid.nl/documenten-en-publicaties/kamerstukken/2012/03/28/ kamerbrief-over-voorwaardelijke-pakkettoelating-farmacie.html. Ref Type: Bill/Resolution
66. Ferrario A, Kanavos P, Managed entry agreements for pharmaceuticals: the European experience Brussels, Belgium: European Medicines Information Network (EMINET) 2013 Ref Type: Report